Intranasal Infection
Intranasal Infection - Related Videos
02:46
Intranasal Murine Herpesvirus Infection in Mice to Assess Host Immune Responses
0 Views •
2026
Source: Zhang, J., et al. P. Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production. J. Vis. Exp. (2014)This video demonstrates intranasal delivery of murine herpesvirus in mice to induce a lung-specific immune response. Lung tissue is subsequently processed to obtain cytokine-containing supernatants for downstream assessment of host immune responses.
02:34
Intranasal Infection of a Mouse with a Pathogenic Influenza Virus
0 Views •
2026
Source: Wang, M., et al, Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice. J. Vis. Exp. (2020).This video demonstrates intranasal infection of a mouse with a pathogenic influenza virus to establish a respiratory tract infection. The procedure outlines the administration of the virus into the nasal cavity. The virus enters host cells, replicates, and activates the immune system.
07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
0 Views •
Cited by 182 •
2013
A method to intranasally administer drugs to awake mice for the purpose of targeting the brain is described. This method allows for repeat dosing over long periods using intranasal administration of drug without anesthesia, and nose-to-brain delivery with minimal systemic exposure.
02:16
Intranasal Immunization with BCG in a Mouse Model
0 Views •
2025
This video demonstrates intranasal BCG immunization in mice, activating both innate and adaptive immune responses, leading to the development of lung-resident memory T cells and effector B cells, thus enhancing protection against Mycobacterium infections.
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
0 Views •
Cited by 14 •
2016
We herein detail the methodology followed to compare protective efficacy and lung immune response induced by intranasal and subcutaneous immunization with BCG in mouse model. Our results show the benefits of pulmonary vaccination and suggest a role for IL17-mediated response in vaccine-induced protection.
FAQs
The epithelial barrier and mucus form the first local defenses encountered by infectious particles in the nasal cavity. These components help limit contact with underlying tissue while also creating the setting in which innate immune cells detect microbial molecules. That detection initiates inflammation, linking surface exposure to early host responses.
Antigen presentation connects early mucosal sensing with longer-term adaptive immunity. After microbial detection and inflammation begin, antigen presentation helps shape adaptive immune responses directed by the host. In infection studies, this link helps explain how events at the airway surface can influence subsequent immune protection.
The distinction lies primarily in purpose and experimental context. Natural intranasal infection represents a route through which disease can occur, whereas a controlled experimental approach provides a framework for examining defined host-pathogen interactions. This research context supports investigation of early airway events, pathogen virulence, mucosal immunity, vaccines, and therapeutics.
At a high level, investigators examine a sequence rather than a single endpoint: exposure brings infectious particles into contact with nasal mucosa; local barriers and innate cells respond; antigen presentation follows; adaptive responses are then evaluated in relation to infection progression or protection. This sequence organizes interpretation of early and later findings.
The nasal and upper respiratory location places the pathogen at an airway surface relevant to respiratory disease. Consequently, the approach can model respiratory transmission while allowing researchers to examine early host-pathogen interactions. These observations help evaluate how pathogen virulence and local immune defenses may influence the course of infection.
This approach provides a setting for evaluating interventions against events that begin at the airway surface. Researchers can examine whether vaccine- or therapy-related findings clarify mucosal immunity, infection progression, or protection. Its value comes from connecting local nasal responses with broader questions about preventing or controlling infection.